Semax + Selank: The Russian Nootropic Peptide Stack Explained (2026)

Traditional nootropics work by modulating neurotransmitter levels — caffeine blocks adenosine receptors, racetams modulate glutamate, adaptogens tweak cortisol. They're all working within the existing signaling environment.

Neuropeptides like Semax and Selank operate at a more fundamental level: they directly regulate the expression of genes encoding growth factors, neurotransmitter receptors, and signaling proteins. They don't just change how much of a chemical is present — they change what proteins the brain is making in the first place. This is why their effects are often described as more lasting and qualitatively different from conventional stimulants.

Both Semax and Selank are registered pharmaceutical drugs in Russia and Ukraine, available by prescription for neurological conditions including ischemic stroke, optic nerve atrophy, anxiety disorders, and cognitive decline. That regulatory context is important — it means they've been through clinical development, not just anecdotal use.

Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from a fragment of ACTH (adrenocorticotropic hormone) — specifically the 4-7 segment — with additional proline modifications that prevent rapid enzymatic degradation. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and patented in 1982.

The key insight that makes Semax remarkable: it doesn't bind ACTH receptors. Despite being derived from ACTH, its modifications redirect its activity toward an entirely different set of targets in the brain — primarily the melanocortin system and the BDNF/TrkB signaling pathway.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide derived from the human immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro tripeptide sequence to improve stability and enhance CNS penetration. It was developed at the same Institute of Molecular Genetics and approved in Russia and Ukraine for treating anxiety disorders and mild-to-moderate depression.

Where Semax is primarily stimulating and cognitively activating, Selank is primarily anxiolytic and mood-stabilizing — but with notable cognitive benefits of its own. The combination addresses cognition from two angles: Semax provides the "engine" of enhanced neural plasticity and focus; Selank removes the "friction" of anxiety and stress-related cognitive interference.

The rationale for stacking these two peptides is straightforward: they address cognitive performance from complementary angles with no pharmacological overlap in their primary mechanisms.

The evidence base for Semax and Selank is stronger than most people in the West realize — primarily because most of it was published in Russian-language journals and registered through the Russian clinical trials database, not ClinicalTrials.gov.

Semax clinical data:

• Approved by the Russian Ministry of Health in 1999 for ischemic stroke recovery and cognitive disorders
• A Phase II/III trial (NCT01753349) evaluated intranasal Semax (0.1%) in acute ischemic stroke, with neurological outcome as primary endpoint ^[6]
• Multiple Russian-published open-label studies show improved neurological recovery scores vs. standard of care in stroke patients
• Published animal studies confirm BDNF induction across hippocampus, cortex, and septum at doses translatable to human research protocols ^[5]

Selank clinical data:

• Approved by the Russian Ministry of Health in 2009 for anxiety and neurasthenia
• Phase III clinical trials demonstrated equivalence to benzodiazepine anxiolytics in reducing Hamilton Anxiety Scale scores, with superior safety profile (no dependence, no sedation) ^[7]
• Published comparative studies vs. diazepam and buspirone showing non-inferior anxiolytic effects ^[7]

The primary limitation for Western research consumers: most human data is published in Russian, conducted under Russian regulatory frameworks, and not yet independently replicated in Western double-blind RCTs. The animal and mechanistic data is highly credible; the human translation relies more on the Russian clinical approval system than on Western peer-reviewed replication.

Both peptides are most commonly administered intranasally (nasal spray) in research settings — a practical and well-studied route that achieves good CNS delivery via olfactory and trigeminal nerve pathways. Subcutaneous injection is an alternative with potentially higher bioavailability but is less commonly used for these particular peptides.

Semax and Selank have notably clean safety profiles relative to their effects — one reason they became approved pharmaceuticals in Russia despite being developed in a Soviet research environment with limited resources for extensive safety testing.

Semax reported effects:

• Mild nasal irritation from the intranasal carrier solution
• Transient headache in the first 1–2 days (typically resolves)
• Occasional mild restlessness or heightened energy, especially if dosed late in the day
• No reported physical dependence or withdrawal in clinical use
• No cortisol or hormonal disruption at standard doses (unlike the parent ACTH molecule)

Selank reported effects:

• Mild nasal irritation
• Rarely, very mild sedation (far less than benzodiazepines)
• No withdrawal or dependence reported in clinical trials
• No significant interaction with alcohol or other CNS depressants at standard doses

The most significant caution is theoretical: Semax's BDNF-upregulating effects are largely beneficial, but very high BDNF can theoretically promote growth in certain tumor types. No clinical evidence connects research doses of Semax to cancer, but individuals with active malignancies should exercise caution.

Unlike many peptides that exist only as lyophilized powders, Semax and Selank are available both as nasal spray solutions (pre-made) and as lyophilized powder for reconstitution. Verify that suppliers provide certificates of analysis covering identity (mass spec), purity (HPLC), sterility, and endotoxin testing.

The Semax + Selank stack represents one of the most pharmacologically rational cognitive-enhancement combinations in the research peptide space. Semax drives neuroplasticity and focus through BDNF upregulation and melanocortin activity; Selank removes cognitive interference by calming the enkephalinergic and GABAergic systems without sedation. They cover complementary territory.

The evidence base is genuinely solid — bolstered by the fact that both are approved pharmaceuticals in Russia with a decades-long clinical track record, not just laboratory curiosities. The gap for Western researchers is the relative scarcity of independent English-language replication in double-blind RCTs. That replication is coming as these compounds gain mainstream research interest.

For a complete picture of the peptide landscape, also see our guides on the CJC-1295 + Ipamorelin stack (for growth hormone optimization) and the Wolverine Stack (for injury recovery).